MedTrace Logo

Long-Term Clinical Follow-Up of Children Enrolled in Stannsoporfin Clinical Trial Protocol No. 64,185-06-2(W)

NCT02685189 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 55

Last updated 2019-10-15

No results posted yet for this study

Summary

The purpose of this protocol is to provide a mechanism to collect Long Term Clinical Data from those babies who participated in the primary Study 64,185-06-2(W)(WS)(ISNHP) "An Open-Label Study Of The Safety And Clinical Pharmacology Of Stanate® In Infants At-Risk For Exchange Transfusion".

Conditions

  • Hyperbilirubinemia

Interventions

OTHER

Previous exposure to stannsoporfin

No intervention in this protocol

Sponsors & Collaborators

  • InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company

    lead INDUSTRY

Principal Investigators

  • Nancy Ruiz, MD · InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company

Eligibility

Min Age
1 Day
Max Age
60 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2016-05-10
Completion
2016-05-10

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02685189 on ClinicalTrials.gov